期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 65, 期 7, 页码 805-812出版社
SPRINGER
DOI: 10.1007/s00262-016-1801-1
关键词
Cancer vaccines; Immune monitoring; Tumor-associated antigen; Melanoma; Hepatocellular cancer; CITIM 2015
资金
- University of Pittsburgh Skin SPORE/National Institutes of Health [P50 CA121973]
- National Institutes of Health [CA104524, CA138635, P30CA047904]
- Melanoma Program
A wide variety of tumor antigens have been targeted in cancer immunotherapy studies. Traditionally, the focus has been on commonly overexpressed antigens shared across many patients and/or tumor types. As the field has progressed, the identity of human tumor rejection antigens has broadened. Immunologic monitoring of clinical trials has slowly elucidated candidate biomarkers of immune response and clinical response, and conversely, of immune dysfunction and suppression. We have utilized MART-1/Melan-A in our melanoma studies and observed a high frequency of immune responses and several significant clinical responses in patients vaccinated with this melanosomal protein. Alpha-fetoprotein is a shared, overexpressed tumor antigen and secreted glycoprotein that we have tested in hepatocellular cancer vaccines. Our recent studies have identified immunosuppressive and immune-skewing activities of this antigen. The choice of target antigen and its form can have unexpected effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据